What are people asking us?
- To subscribe to the monthly Schedule email, go to Schedule subscriptions.
- For all other subscription enquiries, contact us at email@example.com.
Brand and funding changes
New tender listings for August
- Azathioprine (Azamun) tab 25 mg and 50 mg
- Montelukast (Montelukast Mylan) tab 4 mg and 10 mg
- Ceftriaxone (Ceftriaxone-AFT) inj 500 mg and 1 g vial
Calcium carbonate effervescent tablets
We have temporarily listed the Calcium Sandoz brand of effervescent calcium tablets. These are supplied via Section 29 of the Medicines Act 1981 and will replace the Calsource product that has been discontinued. We are working on a longer-term solution.
Flecainide acetate brand change
From 1 July 2019 we are funding Flecainide Controlled Release Teva long-acting capsules. We will fund Flecainide BNM short-acting tablets from 1 September. These brands will replace Tambocor and Tambocor CR.
Lamotrigine brand change
People taking lamotrigine will need to change to the Logem brand by October. See the links below for more information about the change and our decision to change.
Dasatinib - changes to access and distribution
We are changing the access criteria and distibution for dasatinib (Sprycel) tablets used to treat some types of leukaemia.
The changes will mean:
- patients will pick up their dasatinib from their community pharmacy in the same way as other medicines.
- funding will be using a standard Special Authority. Existing patients will automatically receive a new number.
- Some changes to elibility criteria
Insulin pumps - new listings
From 1 November 2018, we listed two new insulin pumps, the MiniMed 640G and the Tandem t:slim X2.
People who are eligible to start on an insulin pump or if the warrantee has expired on their current pump, can choose which pump they would like to start on or change to.
People using an Animas Vibe pump or 50X 3.0 Reservoir will need to change to a new pump.
People may like to discuss their needs with their diabetes healthcare team.
Methylphenidate hydrochloride extended-release - Teva brand new listing
From 1 July 2019, we are listing an additional brand Methylphenidate ER-Teva tablets (18 mg, 27 mg, 36 mg, 54 mg). The current Special Authority and hospital restrictions apply.
Doselupin [dothiepin hydrochloride] discontinuation
The supplier is discontinuing Dopress (dosulepin [dothiepin] ) tablets and capsules as these are no longer being made.
The supplier is discontinuing nitrazepam tablets as these are no longer being made.
Furosemide (frusemide) - restrictions
We have asked pharmacists to dispense furosemide [frusemide] 40 mg tablets monthly due to a supply issue with Diurin 40. We have listed the Apo-Furosemide brand from 1 August 2019.
Sinemet (levodopa with carbidopa)
There is a supply issue with Sinemet. People using Sinemet 100/25 and 200/25 may receive an alternative brand.
People using the 200/50 strength may need to use an alternative strength. Pharmacists have more information about the alternatives for people.
We have been advised of a supply issue with Glucobay (acarbose) 50 mg and 100 mg tablets. Alternative brands are available. We have asked pharmacists to dispense acarbose in monthly lots to assist in managing the available stock.
Ivacaftor (Kaledeco) for cystic fibrosis
PHARMAC received a funding application from the supplier of ivacaftor in 2015. and we will be considering this using our usual processes. PTAC reviewed the application and recommended funding be declined. The Committee considered that, it is not a cure and the data is too immature to determine survival benefit yet.
Updated information from the suppier, Vertex was considered by our Rare Disorders Subcommittee in November 2018.
We havent received a funding application fo rlumacaftir/ivacaftor (Orkambi).
Palbociclib (Ibrance) and trastuzumab emtansine (Kadcyla) breast cancer treatments.
We received a funding application for palbociclib (Ibrance) as initial endocrine therapy for patients with locally advanced or metastatic, HER2-negative, HR-positive breast cancer in February 2018.
We also received an application for trastuzumab emtansine (Kadcyla) for use as a second-line treatment for patients with HER-2 positive metastatic breast cancer who have already been treated with trastuzumab (Herceptin) and a taxane in August 2018.
You can follow progress of these applications on our application tracker.
Doctors are now able to prescribe medicines that contain cannabidiol (CBD). PHARMAC takes a consistent and evidence-based approach to consider the funding of any medicine. No application for funding any products that contain cannabidiol has yet demonstrated to us that it is the next best use of the public funds available for medicines. Contact Ministry of Health to find out more about prescribing cannabis-based products
Continous glucose monitoring system (CGMS)
We are now assessing funding applications for CGMS, including Freestyle Libre. Following progress of these on our application tracker.
Last updated: 31 July 2019